R&D channel feed

Al­to touts new PhI­Ia de­pres­sion da­ta with plans to keep charg­ing for­ward

3 years ago

Day One to file NDA for pe­di­atric brain can­cer drug by sum­mer

3 years ago

Bio­Marin buffs up da­ta on he­mo­phil­ia A gene ther­a­py as FDA de­ci­sion dead­line ap­proach­es

3 years ago
Cell/Gene Tx

Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

3 years ago

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

3 years ago
Deals

Bil­lion­aire-backed TCR start­up scores its first mar­quee in­dus­try al­liance

3 years ago

Doc­tors in­clined to pre­scribe new Alzheimer’s drug de­spite con­cerns

3 years ago

Break­ing: FDA clears sec­ond Alzheimer's drug in 'foun­da­tion­al spark' for field

3 years ago
Pharma
FDA+

GSK, Cure­Vac forge ahead with mid-stage plans for flu, Covid mR­NA vac­cines

3 years ago

An an­tibi­otics biotech be­gins wind-down, lays off near­ly all work­ers

3 years ago
People

Up­dat­ed: Sick­le cell gene edit­ing start­up halts tri­al af­ter flag­ging se­ri­ous side ef­fect in first pa­tient

3 years ago
Cell/Gene Tx

Pfiz­er tags ear­ly re­search pro­grams for 'ex­ter­nal­iza­tion' as it nar­rows fo­cus in rare dis­ease, can­cer

3 years ago

On­ly 1 of 25 can­cer drug de­vel­op­ers fair­ly in­clud­ed mi­nor­i­ty pa­tients over five-year win­dow, BMJ analy­sis finds

3 years ago

Af­ter an EU ap­proval, As­traZeneca and Sanofi's RSV an­ti­body seeks an FDA thumbs-up in Q3

3 years ago

Take­da touts in­ter­im PhI­II da­ta of en­zyme re­place­ment ther­a­py for rare blood dis­ease

3 years ago

Chris Viehbach­er once again sets out to re­vamp R&D at a ma­jor bio­phar­ma. The last try led to his ouster

3 years ago
People
Bioregnum

Gink­go joins Es­per­ovax to at­tempt RNA can­cer treat­ment — in a pill

3 years ago
Deals

While keep­ing eye on snap NASH OK, In­ven­ti­va tests out al­ter­na­tive PhI­II path

3 years ago
FDA+

Pfiz­er leads top-sell­ing phar­ma fore­cast — Eval­u­ate re­port

3 years ago
Pharma

Af­ter three-decade jour­ney, Geron sees new life in PhI­II da­ta on MDS drug, plots path to ap­proval

3 years ago

Hum­ming­bird and Synaf­fix agree to an­ti­body-drug con­ju­gate deal worth up to $150M

3 years ago
Deals

Cap­si­da makes $55M deal with Eli Lil­ly to de­vel­op gene ther­a­pies

3 years ago
Deals
Pharma

De­ci­phera re­vives hopes for Qin­lock with sub­group analy­sis, plots new PhI­II — but mar­ket re­ac­tion is mut­ed

3 years ago

Roivan­t's ul­cer­a­tive col­i­tis drug from Pfiz­er shows promis­ing da­ta in ear­ly read­out

3 years ago
First page Previous page 101102103104105106107 Next page Last page
A service from the Financial Times